Content area

Abstract

Over the past decade, melanoma has led the field in new cancer treatments, with impressive gains in on-treatment survival but more modest improvements in overall survival. Melanoma presents heterogeneity and transcriptional plasticity that recapitulates distinct melanocyte developmental states and phenotypes, allowing it to adapt to and eventually escape even the most advanced treatments. Despite remarkable advances in our understanding of melanoma biology and genetics, the melanoma cell of origin is still fiercely debated because both melanocyte stem cells and mature melanocytes can be transformed. Animal models and high-throughput single-cell sequencing approaches have opened new opportunities to address this question. Here, we discuss the melanocytic journey from the neural crest, where they emerge as melanoblasts, to the fully mature pigmented melanocytes resident in several tissues. We describe a new understanding of melanocyte biology and the different melanocyte subpopulations and microenvironments they inhabit, and how this provides unique insights into melanoma initiation and progression. We highlight recent findings on melanoma heterogeneity and transcriptional plasticity and their implications for exciting new research areas and treatment opportunities. The lessons from melanocyte biology reveal how cells that are present to protect us from the damaging effects of ultraviolet radiation reach back to their origins to become a potentially deadly cancer.

This Review outlines how the developmental pathways that are involved in melanocyte development and skin pigmentation are highjacked by melanoma cells to drive melanomagenesis, progression and therapy resistance.

Details

Title
The journey from melanocytes to melanoma
Author
Centeno, Patricia P. 1   VIAFID ORCID Logo  ; Pavet, Valeria 1 ; Marais, Richard 2   VIAFID ORCID Logo 

 The University of Manchester, Molecular Oncology Group, Cancer Research UK Manchester Institute, Alderley Park, UK (GRID:grid.5379.8) (ISNI:0000000121662407) 
 The University of Manchester, Molecular Oncology Group, Cancer Research UK Manchester Institute, Alderley Park, UK (GRID:grid.5379.8) (ISNI:0000000121662407); Alderly Park, Oncodrug Ltd, Macclesfield, UK (GRID:grid.5379.8) 
Pages
372-390
Publication year
2023
Publication date
Jun 2023
Publisher
Nature Publishing Group
ISSN
1474175X
e-ISSN
14741768
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2819551019
Copyright
© Springer Nature Limited 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.